hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06344000, orgStudyIdInfo id: RICU20240323, briefTitle: Study on Disease Progression and Nutritional Status in Bronchiectasis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-04-15, completionDateStruct date: 2027-04-15, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Wuhan Union Hospital, China, class: OTHER, descriptionModule briefSummary: Bronchiectasis is a common lung disease. The Bronchiectasis Severity Index (BSI) is a widely used assessment system. The body mass index (BMI) is a commonly used measure of nutritional status, but it has its limitations. To provide a more comprehensive assessment, the investigators also consider other nutrition-related indices such as upper arm circumference, calf circumference, skinfold thickness and grip strength. The investigators will specify the relationship between nutritional status and disease progression by measuring nutrition-related indicators and tracking participants' disease progression., conditionsModule conditions: Bronchiectasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: inapplicable, outcomesModule primaryOutcomes measure: Frequency of acute exacerbations of bronchiectasis, secondaryOutcomes measure: Deterioration of lung function, secondaryOutcomes measure: Severity of dyspnoea, secondaryOutcomes measure: Bhalla scores on CT of participants' lungs, secondaryOutcomes measure: Frequency of hospitalisation, secondaryOutcomes measure: Death, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wuhan Union Hospital, city: Wuhan, state: Hubei, zip: 430022, country: China, contacts name: Xiaorong Wang, role: CONTACT, phone: 18627195231, phoneExt: +86, email: rong-100@163.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06343974, orgStudyIdInfo id: 0843, briefTitle: Noninvasive Evaluation of Fetal Hyperinsulinemia With Ultrasound Radiomics, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Turku University Hospital, class: OTHER_GOV, descriptionModule briefSummary: The goal of this observational study is to compare fetal liver ultrasound radiomics between pregnancies complicated by type 1 diabetes and healthy controls.The main questions it aims to answer are:* Are fetal liver ultrasound radiomic features reproducible?* Does fetal liver ultrasound radiomics differ between pregnancies complicated by type 1 diabetes and healthy controls?Participants will undergo ultrasound examination to collect ultrasound data for the analyses., conditionsModule conditions: Pregnancy in Diabetic, conditions: Diabetes Mellitus, Type 1, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Fetal liver ultrasound texture, secondaryOutcomes measure: Birth weight in grams, secondaryOutcomes measure: Birth weight centile, secondaryOutcomes measure: Large for gestational age (LGA), secondaryOutcomes measure: Interventricular septum (IVS) width, secondaryOutcomes measure: Number of pregnancies with neonatal hypoglycemia, secondaryOutcomes measure: Rate of neonatal hypoglycemia treated with oral dextrose gel, secondaryOutcomes measure: Rate of neonatal hypoglycemia treated with intravenous (IV) glucose, secondaryOutcomes measure: Length of treatment for neonatal hypoglycemia, secondaryOutcomes measure: Number of neonates admitted to neonatal intensive care unit (NICU), secondaryOutcomes measure: Length of NICU admission, secondaryOutcomes measure: Number of pregnancies with neonatal respiratory complications related to maternal diabetes, secondaryOutcomes measure: Number of pregnancies with neonatal hyperbilirubinemia, secondaryOutcomes measure: Maternal HbA1c concentration, secondaryOutcomes measure: Glucose management indicator (GMI), secondaryOutcomes measure: Time in glycemic range (TIR), secondaryOutcomes measure: Time above glucose range, secondaryOutcomes measure: Time below glucose range, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Turku University Hospital, city: Turku, country: Finland, geoPoint lat: 60.45148, lon: 22.26869, hasResults: False
protocolSection identificationModule nctId: NCT06343961, orgStudyIdInfo id: 2024-76, briefTitle: Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Jie Zhong, class: OTHER, descriptionModule briefSummary: The study used a new surgical technique: intraoperative fluorescence imaging,In the 1980s, some scholars proposed the concept of intraoperative fluorescein angiography.During vitrectomy, intraoperative fluorescein angiography under 3D microscope can guide the surgeon to observe the non-perfusion area and new blood vessels on the same screen for accurate retinal photocoagulation therapy.Through this technology, the primary retinal disease can be identified in time after the removal of vitreous hemorrhage during surgery, providing effective imaging evidence support for the design of further treatment., conditionsModule conditions: Vascular Retinopathy of Left Eye (Disorder), conditions: Vascular Retinopathy of Right Eye (Disorder), conditions: Diabetic Retinopathy, conditions: Retinal Vein Occlusion, conditions: Retinal Vasculitis, conditions: Vitreous Hemorrhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A total of 80 patients with vitreous hemorrhage diagnosed in Sichuan Provincial People's Hospital from January 2024 to December 2025 were selected. The number of included cases was calculated according to the minimum sample size of 200 patients with vitreous hemorrhage in our hospital, 95% confidence level and 5% confidence interval, and the calculated result was 79. The included cases were equally divided by random number method. 40 patients in the control group were given vitrectomy and other conventional operations such as retinal laser photocoagulation. In contrast group, 40 patients were given vitrectomy combined with intraoperative fluorescein angiography and other conventional operations such as retinal laser photocoagulation. The diagnosis rate of primary disease cause, observation rate of neovascularization and non-perfusion area, visual acuity, visual field, thickness of macular fovea and postoperative complications (ciliary detachment, secondary vitreous hemorrhage, neovascu, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Intraoperative Fluorescein Angiography, outcomesModule primaryOutcomes measure: best corrected visual acuity, primaryOutcomes measure: Central retinal thickness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343948, orgStudyIdInfo id: BL-B01D1-306, briefTitle: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Sichuan Baili Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., descriptionModule briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy., conditionsModule conditions: HR+HER2- Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 382, type: ESTIMATED, armsInterventionsModule interventions name: BL-B01D1, interventions name: Eribulin, interventions name: Vinorelbine, interventions name: Gemcitabine, interventions name: Capecitabine, outcomesModule primaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Treatment Emergent Adverse Event (TEAE), secondaryOutcomes measure: Anti-drug antibody (ADA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital Chinese Academy of Medical Sciences, city: Beijing, state: Beijing, country: China, contacts name: Binghe Xu, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06343935, orgStudyIdInfo id: YY-20394-014, briefTitle: A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Shanghai YingLi Pharmaceutical Co. Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode)., conditionsModule conditions: Indolent B-cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 88, type: ESTIMATED, armsInterventionsModule interventions name: Linperlisib, outcomesModule primaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Objective response rate, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Adverse event, secondaryOutcomes measure: Serious adverse event, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343909, orgStudyIdInfo id: REC/RCR & AHS/23/0197Ayesha, briefTitle: Foot and Hip Abductor Strengthening in Patients With Knee Osteoarthritis., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-23, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: The study will be Randomized controlled trail, Subject diagnosed with knee osteoarthritis meeting predetermined inclusion and exclusion criteria will be divided into two groups.Pre assessment will be done using pain, ROM, function, foot arches and knee alignment as subjective measurement through KOOS questionnaire, goniometer, 2D frontal plane projection, Berkemann foot prints using ink and paper ,30s chair stand test, nine step stair climb,40m fast paced walk test,Global rating of change score respectively . One group will be treated with hip abductor strengthening exercise along with conventional exercises and second group will be treated with intrinsic foot muscle strengthening exercise along with conventional exercises. Post treatment values recorded after the session.After data collection from defined study setting,data will be entered and analyzed at Riphah International University,Lahore, conditionsModule conditions: Knee Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Hip abductor strengthening exercise, interventions name: Intrinsic foot muscle strengthening along with conventional exercises, outcomesModule primaryOutcomes measure: Knee Osteoarthritis Outcome Score (KOOS), primaryOutcomes measure: Berkemann foot prints, secondaryOutcomes measure: Frontal plane projection, secondaryOutcomes measure: Goniometer, secondaryOutcomes measure: 30 seconds chair stand test, secondaryOutcomes measure: Overall self-perception by Global Rating of Change Score, secondaryOutcomes measure: 9 step stairs climb test., secondaryOutcomes measure: 40-m fast-paced walk test, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: THQ hospital KRK., status: RECRUITING, city: Lahore, state: Punjab, country: Pakistan, contacts name: Ayesha Anwar, DPT, role: CONTACT, phone: 03340003448, email: ayeshaanwarali123@gmail.com, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06343896, orgStudyIdInfo id: AnkaraCHBilkent-tntaygurt, briefTitle: Evaluation of Sedation Depth and Reliability With Integrated Pulmonary Index (IPI) Follow-up in Pediatric Radiological Interventions, acronym: IPI, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-15, completionDateStruct date: 2024-10-15, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: In this study, we aimed to investigate the predictability of possible respiratory complications and the effect of the addition of the integrated pulmonary (EPI) score to the evaluation of the patient's respiratory index status in addition to the SPO2 measurement available in standard ASA monitoring in pediatric patients undergoing interventional radiological procedures under sedoanesthesia., conditionsModule conditions: Sedation, conditions: BIS, conditions: Integrated Pulmonary Index, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: monitorization reliability, outcomesModule primaryOutcomes measure: EVALUATION OF IPI RELIABILITY IN PEDIATRIC PATIENTS, secondaryOutcomes measure: BİS correlation with the IPI, secondaryOutcomes measure: pulse oximetry correlation with the IPI, secondaryOutcomes measure: noninvasive blood pressure, secondaryOutcomes measure: heart rate, secondaryOutcomes measure: respiratory rate, secondaryOutcomes measure: end tidal carbondioxide, secondaryOutcomes measure: apnea and hypoxia conditions that develop in the patient during anesthesia, secondaryOutcomes measure: postoperative recovery time, secondaryOutcomes measure: intraoperative total dose of medication used, secondaryOutcomes measure: postoperative nausea and vomiting, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ankara City Hospital, Bilkent, status: RECRUITING, city: Ankara, country: Turkey, contacts name: tugbanur taygurt, role: CONTACT, phone: +905322005632, email: tugbanurtaygurt@gmail.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06343883, orgStudyIdInfo id: 24-353, briefTitle: Investigation of Low-intensity Focused Ultrasound Pressure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-07, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Virginia Polytechnic Institute and State University, class: OTHER, descriptionModule briefSummary: Investigating the relationship between input pressure of low-intensity focused ultrasound and an evoked potential in both eeg and fMRI., conditionsModule conditions: Somatic Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Primary cohort (safety) will be collected prior to full study collection. Primary collection will involve highest pressure application and follow-up safety scans (MRI) to be reviewed by a Neuroradiologist. Once cleared - parallel design will be utilized for eeg and fMRI cohorts. Both cohorts will receive 3 LIFU pressures randomized over 3 study visits. Electrical stimulations will be applied pre and post LIFU administration to induce somatosensory evoked potentials (SEPs)., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, maskingDescription: No masking, no sham. All subjects will receive all conditions, all of which are active., enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: low-intensity focused ultrasound - low pressure, interventions name: low-intensity focused ultrasound - medium pressure, interventions name: low-intensity focused ultrasound - high pressure, outcomesModule primaryOutcomes measure: Report of Symptoms Questionnaire, primaryOutcomes measure: MRI, secondaryOutcomes measure: EEG, secondaryOutcomes measure: fMRI, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fralin Biomedical Research Institute at VTC, city: Roanoke, state: Virginia, zip: 24016, country: United States, contacts name: Jessica Florig, MPH, role: CONTACT, phone: 540-526-2261, email: jnw@vtc.vt.edu, contacts name: Wynn Legon, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.27097, lon: -79.94143, hasResults: False
protocolSection identificationModule nctId: NCT06343870, orgStudyIdInfo id: ESTIME, briefTitle: Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME), acronym: ESTIME, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of Sao Paulo General Hospital, class: OTHER, descriptionModule briefSummary: Estrogen and androgen deficiencies negatively impact the quality of life of women at different stages of life, especially after menopause. New modalities and new therapeutic alternatives have been researched. Parenteral administration of estradiol and testosterone could be effective to treat symptoms secondary to estrogen and androgen deficiencies and minimize these adverse events. This study evaluates the efficiency of subdermal implant-bioabsorbable use in women with menopausal symptoms associated with secondary estrogen and androgen deficiencies in women with natural menopause, premature ovarian failure or surgical menopause due to cervical cancer. Pharmacokinetic, biochemical, metabolic, thromboembolic and hormonal data will be evaluated, as well as the effects on quality of life, menopausal symptoms and sexual function after treatment., conditionsModule conditions: Menopause, conditions: Testosterone Deficiency, conditions: Estrogen Deficiency, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel Assignment, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: testosterone pellet (100 mg), interventions name: Placebo, outcomesModule primaryOutcomes measure: Evaluate hormonal, metabolic thromboembolic and clinical effects on climacteric symptoms, secondaryOutcomes measure: Evaluate response in quality of life and sexual function, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False